Israel-based medical device company Medasense Biometrics has obtained CE mark approval for its pain monitoring device, PMD200 to aid clinicians in providing personalised pain relief.
The new device will enable physicians to objectively examine a patient’s pain in critical care situations, where patients are unable to communicate the condition, thereby paving the way for a better pain management.
The PMD200 has been developed as a pain monitoring device based on the patented NOL technology that quantifies patients’ physiological response to pain.
The system is convenient to use and features a non-invasive finger probe which receives physiological signals from four different sensors and calculates dozens of pain-related physiological parameters.
The data is analysed by artificial intelligence algorithms and is then converted into a single pain index, as the Nociception Level (NOL) index, where zero denotes no pain and 100 denotes extreme pain.
The NOL index has demonstrated efficacy in intraoperative pain assessment in clinical validation studies conducted across European and Canadian hospitals.
The company is exploring using the NOL Index in other forms of pain such as chronic pain including long-term back pain.
Leiden University Medical Center in the Netherlands Department of Anaesthesiology Professor Albert Dahan said: "We have been studying the PMD device for a number of years now, and I believe that the NOL index may allow for more balanced anesthesia, as for the first time we are able to titrate analgesic medication to patients' needs.
“In the upcoming weeks the LUMC will be adding PMD200 devices into the operating rooms, in the future I hope to see the NOL index integrated into other monitors as it provides significant decision support information and can potentially positively impact patient outcomes".
The pain monitoring system is expected to aid in optimisation and personalisation of pain treatment by avoiding excess or under use of pain medication that can lead to significant complications.